Please assess the completion status of the following clinical trial:

Trial Title: Patient Experience Study of Deoxycholic Acid Injection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~1. Submental fat graded by the Investigator as 2 (moderate) or 3 (severe) using the Clinician-Reported Submental Fat Rating Scale (CR-SMFRS) and graded by the subject as 2 (moderate amount) or 3 (large amount) using the Patient-Reported Submental Fat Rating Scale (PR-SMFRS)~2. Dissatisfaction with the appearance of the submental area expressed by the subject as a rating of 0, 1, or 2 using the Subject Self Rating Scale (SSRS)~3. History of stable body weight for at least 6 months and body mass index (BMI) of ≤ 40 kg/m².~4. Acceptable skin laxity as determined by the investigator~5. Agreement by the subject to refrain from making significant changes, in the documented judgment of the investigator, to his or her dietary or exercise habits during the course of the subject's participation.~6. Agreement to forego any treatment or behavior (e.g., unshaven facial hair)~7. Signed informed consent obtained before any study-specific procedure is performed.~Exclusion Criteria:~1. No prior intervention for submental fullness or recent cosmetic procedure in the neck or chin area~2. Absence of clinically significant health problems~3. Body mass index \> 40.0 kg/m² as determined prior to randomization.~4. History of drug or alcohol abuse.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Paradigm 1 / Deoxycholic Acid Injection (Type: EXPERIMENTAL): Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL (based on Baseline CR-SMFRS grade 2 or 3, respectively) on Day 0 and a cold compress applied to the treatment area.
- Paradigm 1/ Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0 and a cold compress applied to the treatment area.
- Paradigm 2 / Deoxycholic Acid Injection (Type: EXPERIMENTAL): Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL on Day 0, topical and injectable anesthetics (lidocaine/epinephrine) and a cold compress applied to the treatment area.
- Paradigm 2 / Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0, topical and injectable anesthetics and a cold compress applied to the treatment area.
- Paradigm 3 / Deoxycholic Acid Injection (Type: EXPERIMENTAL): Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL on Day 0, oral antihistamine and anti-inflammatory agents (loratadine and ibuprofen), topical and injectable anesthetics and a cold compress applied to the treatment area.
- Paradigm 3 / Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0, oral antihistamine and anti-inflammatory agents, topical and injectable anesthetics and a cold compress applied to the treatment area.
- Paradigm 4 / Deoxycholic Acid Injection (Type: EXPERIMENTAL): Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL on Day 0, a compression chin strap, oral antihistamine and anti-inflammatory agents, topical and injectable anesthetics and a cold compress applied to the treatment area.
- Paradigm 4 / Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0, a compression chin strap, oral antihistamine and anti-inflammatory agents, topical and injectable anesthetics and a cold compress applied to the treatment area.

Based on this trial design, predict the completion outcome and termination type (if applicable).